Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System

Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Francisco De Assis Acurcio, Haliton Alves De Oliveira, Adriana Maria Kakehasi, Augusto Afonso Guerra, Marion Bennie, Brian Godman, Juliana Alvares

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. Methods: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used. Results: A total of 266 RA patients started treatment with adalimumab or etanercept. Adalimumab was the most widely used bDMARD (70%). In total, 46% achieved remission or low-disease activity at 12 months with no difference in effectiveness between them (p = 0.306). bDMARDs were more effective in patients who had better functionality at treatment onset and had spent longer in education. Conclusion: This real-world study demonstrated that adalimumab and etanercept are equal alternatives for RA treatment and both were well tolerated.

LanguageEnglish
Pages539-549
Number of pages11
JournalJournal of Comparative Effectiveness Research
Volume5
Issue number6
Early online date19 Sep 2016
DOIs
Publication statusPublished - 1 Nov 2016

Fingerprint

Antirheumatic Agents
Rheumatoid Arthritis
Public Health
Brazil
Cohort Studies
Therapeutics
Prospective Studies
Safety
Education
Costs and Cost Analysis
Etanercept
Adalimumab
Health

Keywords

  • adalimumab
  • Brazil
  • cohort study
  • effectiveness
  • etanercept
  • rheumatoid arthritis

Cite this

Dos Santos, J. B. R., Almeida, A. M., Acurcio, F. D. A., De Oliveira, H. A., Kakehasi, A. M., Guerra, A. A., ... Alvares, J. (2016). Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research, 5(6), 539-549. https://doi.org/10.2217/cer-2016-0027
Dos Santos, Jéssica Barreto Ribeiro ; Almeida, Alessandra Maciel ; Acurcio, Francisco De Assis ; De Oliveira, Haliton Alves ; Kakehasi, Adriana Maria ; Guerra, Augusto Afonso ; Bennie, Marion ; Godman, Brian ; Alvares, Juliana. / Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. In: Journal of Comparative Effectiveness Research. 2016 ; Vol. 5, No. 6. pp. 539-549.
@article{139b25edfb6243d4981d02856acfa7c8,
title = "Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System",
abstract = "Aim: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. Methods: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used. Results: A total of 266 RA patients started treatment with adalimumab or etanercept. Adalimumab was the most widely used bDMARD (70{\%}). In total, 46{\%} achieved remission or low-disease activity at 12 months with no difference in effectiveness between them (p = 0.306). bDMARDs were more effective in patients who had better functionality at treatment onset and had spent longer in education. Conclusion: This real-world study demonstrated that adalimumab and etanercept are equal alternatives for RA treatment and both were well tolerated.",
keywords = "adalimumab, Brazil, cohort study, effectiveness, etanercept, rheumatoid arthritis",
author = "{Dos Santos}, {J{\'e}ssica Barreto Ribeiro} and Almeida, {Alessandra Maciel} and Acurcio, {Francisco De Assis} and {De Oliveira}, {Haliton Alves} and Kakehasi, {Adriana Maria} and Guerra, {Augusto Afonso} and Marion Bennie and Brian Godman and Juliana Alvares",
year = "2016",
month = "11",
day = "1",
doi = "10.2217/cer-2016-0027",
language = "English",
volume = "5",
pages = "539--549",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6313",
number = "6",

}

Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. / Dos Santos, Jéssica Barreto Ribeiro; Almeida, Alessandra Maciel; Acurcio, Francisco De Assis; De Oliveira, Haliton Alves; Kakehasi, Adriana Maria; Guerra, Augusto Afonso; Bennie, Marion; Godman, Brian; Alvares, Juliana.

In: Journal of Comparative Effectiveness Research, Vol. 5, No. 6, 01.11.2016, p. 539-549.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System

AU - Dos Santos, Jéssica Barreto Ribeiro

AU - Almeida, Alessandra Maciel

AU - Acurcio, Francisco De Assis

AU - De Oliveira, Haliton Alves

AU - Kakehasi, Adriana Maria

AU - Guerra, Augusto Afonso

AU - Bennie, Marion

AU - Godman, Brian

AU - Alvares, Juliana

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Aim: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. Methods: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used. Results: A total of 266 RA patients started treatment with adalimumab or etanercept. Adalimumab was the most widely used bDMARD (70%). In total, 46% achieved remission or low-disease activity at 12 months with no difference in effectiveness between them (p = 0.306). bDMARDs were more effective in patients who had better functionality at treatment onset and had spent longer in education. Conclusion: This real-world study demonstrated that adalimumab and etanercept are equal alternatives for RA treatment and both were well tolerated.

AB - Aim: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. Methods: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used. Results: A total of 266 RA patients started treatment with adalimumab or etanercept. Adalimumab was the most widely used bDMARD (70%). In total, 46% achieved remission or low-disease activity at 12 months with no difference in effectiveness between them (p = 0.306). bDMARDs were more effective in patients who had better functionality at treatment onset and had spent longer in education. Conclusion: This real-world study demonstrated that adalimumab and etanercept are equal alternatives for RA treatment and both were well tolerated.

KW - adalimumab

KW - Brazil

KW - cohort study

KW - effectiveness

KW - etanercept

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84992154422&partnerID=8YFLogxK

U2 - 10.2217/cer-2016-0027

DO - 10.2217/cer-2016-0027

M3 - Article

VL - 5

SP - 539

EP - 549

JO - Journal of Comparative Effectiveness Research

T2 - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6313

IS - 6

ER -